Events Archives - Page 70 of 128

6 minute read

UroGen Pharma Ltd. Presents Retrospective Study At AUA 2023 Provides Evidence Of Similar Outcomes Utilizing JELMYTO In The Treatment Of UTUC Of The Ureter And Renal Pelvis

April 30, 3:52 PM

UroGen Pharma Ltd. (NASDAQ:URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today highlights the results of a sub-analysis from the

URGN

5 minute read

Actinium Highlights Administration Of Targeted Radiotherapy Iomab-B Across Various BMT Centers With Ease And Without Increasing Radiation Exposure Risks To Treating Nursing Staff In The Pivotal Phase 3 SIERRA Trial At The 48th Annual ONS Congress

By Happy Mohamed

April 28, 8:13 AM

- 24 leading bone marrow transplant (BMT) centers that perform over 30% of transplants in the U.S. participated in the SIERRA trial that enrolled patients with active relapsed or refractory acute

ATNM

2 minute read

Veracyte Announces Five Abstracts Providing Molecular Insights Into Prostate And Other Cancers To Be Presented At The 2023 ASCO Annual Meeting

By Happy Mohamed

April 28, 7:10 AM

Veracyte, Inc. (NASDAQ:VCYT) today announced that five abstracts providing new molecular insights into prostate and other cancers will be presented at the 2023 American Society of Clinical Oncology (ASCO) Annual

VCYT

1 minute read

Taysha Gene Therapies Announces Presentation On New Preclinical Data For TSHA-102 In Rett Syndrome At Upcoming American Society Of Gene And Cell Therapy 26th Annual Meeting

By Happy Mohamed

April 27, 4:55 PM

Taysha Gene Therapies, Inc. (NASDAQ:TSHA), a clinical-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system

TSHA

2 minute read

DraftKings Pushes Diversification Efforts With Streaming Video Service: What Investors Should Know

By Chris Katje

April 27, 1:06 PM

Sports betting giant DraftKings Inc (NASDAQ: DKNG) has grown from a leading daily fantasy sports operator to a sports betting leader over the years and has also looked to diversify itself in the sports sector. Here’s a look at its new efforts.

DKNG

7 minute read

Actinium Announces Pivotal Phase 3 SIERRA Trial Results Of Iomab-B Showcased To The European Transplant Community In Oral Presentation At The European Society For Blood And Marrow Transplantation Annual Meeting

By Happy Mohamed

April 27, 10:38 AM

- EBMT oral presentation builds awareness for Iomab-B and the SIERRA trial results with the European transplant community that performs twice as many transplants compared to the U.S. - Iomab-B

ATNM

1 minute read

Events
News

Teva To Launch New Growth Strategy At Investor Day On Thursday, May 18, 2023

By Happy Mohamed

April 27, 8:43 AM

Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will host an Investor Day on Thursday, May 18, 2023 to launch its new growth strategy and portfolio priorities. The event will take place

TEVA

3 minute read

ReShape Lifesciences To Present Data On Its Proprietary Diabetes Bloc-Stim Neuromodulation Device At The Keystone Symposia On Type 2 Diabetes

By Happy Mohamed

April 27, 8:39 AM

ReShape Lifesciences™ (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced it will present data on its proprietary Diabetes Bloc-Stim

RSLS

4 minute read

Coherus And Junshi Biosciences Announce Toripalimab Studies To Be Presented At The 2023 American Society Of Clinical Oncology Annual Meeting

By Happy Mohamed

April 27, 8:26 AM

Shanghai Junshi Biosciences Co., Ltd ("Junshi Biosciences", HKEX: 1877; SSE: 688180) and Coherus BioSciences, Inc. (("Coherus", NASDAQ:CHRS) today announced that data presentations of four toripalimab

CHRS

3 minute read

PDS Biotech To Present Updated Data At 2023 American Society Of Clinical Oncology Annual Meeting Highlighting Combination Of PDS0101 And KEYTRUDA In Head And Neck Cancer Patients

By Happy Mohamed

April 27, 8:19 AM

PDS Biotechnology Corporation (NASDAQ:PDSB), a clinical-stage immunotherapy company developing a growing pipeline of targeted immunotherapies for cancer and infectious disease, announced the presentation of updated data

PDSB